MedTrace Logo

AL Amyloidosis and Anti-CD38-Daratunumab

NCT06571864 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-08-26

No results posted yet for this study

Summary

AL Amyloidosis and anti-CD38

Conditions

  • Amyloidosis

Interventions

DRUG

Anti-CD38 Monoclonal Antibody

Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Principal Investigators

  • Dario Roccatello · ASL Città di Torino, Torino, IT

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-02
Primary Completion
2024-01-02
Completion
2024-02-02

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06571864 on ClinicalTrials.gov